Stephen Lam Chan, MBBS, MD (CUHK), FRCP, discusses the lack of benefit with adjuvant pembrolizumab in HCC following a complete radiologic response.
Stephen Lam Chan, MBBS, MD
Advertisement
Stephen Lam Chan, MBBS, MD, is a professor in the department of Clinical Oncology, The Chinese University of Hong Kong.
Articles by Stephen Lam Chan, MBBS, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Legubicin More Than Doubles PFS in Advanced Soft Tissue Sarcoma
3
Adjuvant CDK4/6 Inhibitors Gain Ground as Oral SERDs Emerge to Tackle Endocrine Resistance in Early HR+ Breast Cancer
4
Gamgertamig Nets FDA Fast Track Designation in Autoimmune Hemolytic Anemia and Immune Thrombocytopenia
5